Fig. 8

Responses of patients with CRC to anlotinib therapy. A The CONSORT diagram shows the patient flow through the clinical trial. B Distribution of circHAS2 expression levels in 70 patients with CRC as represented by relative expression level. C Diagram of the clinical trial design for the treatment of patients with advanced CRC. D Computed tomography scans of three representative CRC patients collected at baseline and after anlotinib treatment. The lesions were significantly reduced after treatment. E The best tumor response and maximum percent change from baseline were in the sum of target-lesion diameters during anlotinib treatment in an individual patient according to RECIST v1.1. F Serum CEA, CA125, and CA19-9 level of Group A (patient1,5, and 7) during the indicated treatment. G Schematic diagram of circHAS2 activating CCNE2 to promote cell proliferation and anlotinib sensitivity in colorectal cancer by Figdraw (www.figdraw.com)